In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer

Acta Medica Okayama

Volumn 66, Issue 3, 2012, Pages 271-277

  Lee, Shin Wha ^a   Kim, Yong Man ^a   Kim, Moon Bo ^b   Kim, Dae Yeon ^a   Kim, Jong Hyeok ^a   Nam, Joo Hyun ^a   Kim, Young Tak ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Metabio Institute   (South Korea)

Author keywords

Carboplatin; Chemosensitivity; Epithelial ovarian cancer; HDRA (histoculture drug response assay)

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; DRUG SCREENING; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY CARCINOMA; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84864775504     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Boring CC, Squires TS and Tong T: Cancer Statistics, 1991. CA Cancer J Clin (1991) 41: 19-36.
2. Sevin BU and Perras J: Tumour heterogeneity and in vitro chemo- sensitivity testing in ovarian cancer. Am J Obstet Gynecol (1997) 176: 759-768.
3. Hoffman RM: In vitro sensitivity assay in cancer: a review. J Clin Lab Anal (1991) 5: 133-143.
4. Hoffman RM: In vitro assays for chemotherapy sensitivity. Crit Rev Oncol Hematol (1993) 15: 99-111.
5. Brown E and Markman M: Tumor chemosensitivity and chemore- sistance assays. Cancer (1996) 77: 1020-1025.
6. Hoffman RM: Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells (1991) 3: 86-92.
7. Robbins KT, Connors KM, Storniolo AM, Hanchett C and Hoffman RM: Sponge-gel-supported histoculture drug-response assay for head and neck cancer: Correlations with clinical response to cis- platin. Arch Otolaryngol Head Neck Surg (1994) 120: 288-292.
8. Furukawa T, Kubota T and Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res (1995) 1: 305-311.
9. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, Nagura H, Ogawa N and Hoffman RM: Potential of the histoculture drug response assay to contribute to cancer patient survival. Clin Cancer Res (1995) 1: 1537-1543.
10. Furukawa T, Kubota T, Tanino H, Oura S, Yuasa S, Murate H, Morita K, Kozakai K, Yano T and Hoffman RM: Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res (2000) 20: 3657-3658.
11. Hoffman RM: To do tissue culture in two or three dimensions? That is the question. Stem Cells (1993) 11: 105-111.
12. Tanino H, Oura S, Hoffman RM, Kubota T, Furukawa T, ArimotoJ, Yoshimasu T, Hirai I, Bessho T, Suzuma T, Sakurai T and Naito Y: Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res(2001)21: 4083-4086.
13. Kim R, Manabu E and Tanabea K: Chemosensitivity testing for gastrointestinal cancer: survival benefit potential and limitations. Anticancer Drugs (2003) 14: 715-723.
14. Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR and Hoffman RM: Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res (2000) 20: 2049-2054.
15. Lee HP, Seo SS, Ryu SY, Kim JH, Bang YJ, Park SY, Nam JH, Kang SB, Lee KH and Song YS: Phase H evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol (2008) 109: 359-363.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 92: 205-216.
17. ColeSP: Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol (1986) 17: 259-263.
18. O'Toole SA, Sheppard BL, McGuinness EP, Gleeson NC, Yoneda M and Bonnar J: The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. Cancer Detect Prev (2003) 27: 47-54.
19. Inaba M, Tashiro T, Sato S, Ohnishi Y, Tanisaka K, Kobayashi H and Koezuka M: In vitro-'m vivo correlation in anticancer drug sen sitivity test using AUC-based concentrations and collagen gel droplet-embedded culture. Oncology (1996) 53: 250-257.
20. Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H and Noguchi S: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer (2002) 98: 450-455.
21. Freuhauf JP: In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer (2002) 9: 171-182.
22. Lee SW, Kim YM, Kim MB, Kim DY, Kim JH, Nam JH and Kim YT: Chemosensitivity of Uterine Cervical Cancer Demonstrated by the Histoculture Drug Response Assay. Tohoku J Exp Med (2009) 219: 277-282.
23. Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ and Fruehauf JP: Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol (2002) 87: 8-16.
24. Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ and Fruehauf JP: Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol (2005) 98: 360-368.
25. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage in and stage IV ovarian cancer. N Eng J Med (1996) 334: 1-6.
26. DiSaia PJ and Tewari KS: Recent advancements in the treatment of epithelial ovarian cancer. J Obstet Gynaecol Res (2001) 27: 61-75.
27. Brigulová K, Cervinka M, Tošner J and Sedláková I: Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol In Vitro (2010) 24: 2108-2115.
28. Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, Susumu N, Udagawa Y and Nozawa S: Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response. Int J Gynecol Cancer (2005) 15: 445-452.